Tau, ubiquitin, and alpha B-crystallin immunohistochemistry define the principal causes of degenerative frontotemporal dementia.
OBJECTIVE
We investigated the use of immunostaining with antibodies to tau, ubiquitin, and alpha B-crystallin in defining a protocol for the staged neuropathologic examination of brains from patients with a progressive frontotemporal dementia.


METHODS
Brains obtained from 50 patients dying with the clinical diagnosis of frontotemporal dementia were examined histopathologically to define pathologic distinctions.


METHODS
Two university hospital neuropathology departments.


RESULTS
Anti-tau immunostaining defined corticobasal degeneration, Alzheimer's disease, and Pick's disease; antiubiquitin defined motor neuron disease with dementia. The remaining brains have frontal lobe degeneration: the use of alpha B-crystallin immunostaining, on these, to detect ballooned neurons may help to define two groups of patients, one of which we believe may represent a variant of Pick's disease.


CONCLUSIONS
These findings indicate that immunostaining with these antibodies is essential for the evaluation of frontal dementia.
Cooper
P N
PN
Department of Pathology, Manchester University Medical School, England.
Jackson
M
M
Lennox
G
G
Lowe
J
J
Mann
D M
DM
D000906:Antibodies / Q000032:analysis; D003459:Crystallins / Q000032:analysis*; D003704:Dementia / Q000209:etiology / Q000378:metabolism* / Q000473:pathology*; D005625:Frontal Lobe / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D013702:Temporal Lobe / Q000378:metabolism* / Q000473:pathology; D014452:Ubiquitins / Q000032:analysis*; D016875:tau Proteins / Q000032:analysis*
D000906:Antibodies; D003459:Crystallins; D014452:Ubiquitins; D016875:tau Proteins